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ABSTRACT

Tangeman, Larissa Jordan. M.S., Microbiology and Immunology Program, Wright State
University, 2011. Targeted Knockdown of AMP-activated Protein Kinase Alpha 1 and
Alpha 2 Catalytic Subunits.

AMP-activated protein kinase (AMPK) regulates cellular metabolism and
promotes ATP production when energy is depleted. Evidence suggests that AMPK may
be involved in oxygen sensing by carotid body cells, which are responsible for regulating
the breathing rate to maintain proper blood oxygen levels. There are two isoforms of the
catalytic α subunit, AMPKα1 and AMPKα2, which could be involved in oxygen
sensing. Here, the production of a short hairpin RNA (shRNA) targeting both catalytic
isoforms of AMPK in human, mouse, and rat is described. The shRNA causes significant
knockdown of both isoforms of AMPKα in mouse and human cells and a significant
reduction in AMPK activity, measured as phosphorylation of a direct target. This shRNA
will be used to generate a rat model with tissue-specific knockdown of AMPKα1 and 2
using a Cre-Lox recombination system to determine the role of AMPK in oxygen sensing
by the carotid body.

iii

TABLE OF CONTENTS

Page
I. INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1

AMP-activated protein kinase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1

Carotid body . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2

Studying AMPK activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3

RNA interference . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3

Cre-Lox system . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7

Tissue-specific knockdown . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .10

Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

II. MATERIALS AND METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16

Cloning and cell culture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16
iv

siRNA and shRNA design. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

Transfection and infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .22

Western blotting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23

Data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

III. RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25

siRNA-mediated knockdown of AMPK alpha . . . . . . . . . . . . . . . . . . . . . . . . . 25

shRNA-mediated knockdown of AMPK alpha . . . . . . . . . . . . . . . . . . . . . . . . .30

Knockdown of AMPK alpha in mouse and human cells . . . . . . . . . . . . . . . . . .35

Functional knockdown of AMPK alpha . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40

Expression of TH promoter-driven constructs. . . . . . . . . . . . . . . . . . . . . . . . . .40

Cre recombinase-driven recombination. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45

v

IV. DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48

AMPK alpha 1 and 2 knockdown . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48

Tissue-specific constructs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49

Disrupted U6 promoter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50

Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51

V. APPENDIX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .54
VI. REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .55

vi

LIST OF FIGURES

Page
Figure 1. Diagram of RNAi pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5

Figure 2. Diagram of Cre recombinase-mediated recombination . . . . . . . . . . . . . . . . . . . 8

Figure 3. Structures of shRNA constructs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11

Figure 4. Structure of virus producing tissue-specific silencing . . . . . . . . . . . . . . . . . . . 14

Figure 5. siRNA-mediated knockdown of AMPK alpha 1 and 2 in NIH3T3 cells . . . . .28

Figure 6. shRNA-mediated knockdown of AMPK alpha 1 and 2 in NIH3T3 cells with
different loop sequences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33

Figure 7. shRNA-mediated knockdown of AMPK alpha 1 and 2 in mouse and human
cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .36

Figure 8. Transfection efficiency of NIH3T3 and HEK293 cells . . . . . . . . . . . . . . . . . . 38

Figure 9. shRNA-mediated knockdown of AMPK alpha activity in HEK293 cells . . . .41

vii

Figure 10. Expression of TH promoter-driven constructs . . . . . . . . . . . . . . . . . . . . . . . .43

Figure 11. In vitro recombination of disrupted U6 promoter construct with Cre
recombinase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46

viii

LIST OF TABLES

Page
Table 1. Base plasmids used to create constructs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

Table 2. Cloned constructs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .20

Table 3. Identification of a globally conserved sequence in AMPK alpha 1 and 2 . . . . .26

Table 4. Identification of a conserved sequence in AMPK alpha 2 . . . . . . . . . . . . . . . . .27

Table 5. Design of shRNA loop sequences and sequences of shRNA oligos . . . . . . . . .31

Table 6. Design of global AMPK alpha 1 and 2 shRNA and corresponding control
shRNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32

ix

ACKNOWLEDGMENTS

I would like to acknowledge and thank the large number of people without
whom this work would not have been possible. First, I would like to thank Dr. Thomas
Brown for giving me the opportunity to work in his lab and for his continual assistance
and support. This experience shaped my future career goals into what they are today. I
would also like to thank my committee, Dr. Brown, Dr. Christopher Wyatt, and Dr.
Courtney Sulentic, for their guidance throughout my project.
I would like to thank the members of the Brown Lab for their help and company
for the past two years: Chanel Keoni, Renee Albers, Erica Baker, Rebecca Bricker,
Deanne Jacobs, Christina Fung, Susan Robinson, Prakash Arumagum, Elizabeth
Ludvigson, and Samantha Venkatesh. I would especially like to thank Renee and Erica
for their excellent technical assistance and Chanel for helping me get my bearings when I
first started. I would also like to thank the members of the Wyatt Lab, especially Dr.
Wyatt, Barbara Barr, and Heidi Jordan, and Dr. R. Putnam for helping to create a very
friendly and cooperative work environment.
I would like to thank Dr. James Lessard from Cincinnati Children’s Hospital
Medical Center for his gift of the anti-actin C4 antibody. I would like to thank Dr. C.
Sulentic, Dr. C. Wyatt, Dr. T. Bubulya, Dr. M. Leffak, Dr. D. Cool, and Dr. J.
Cambronero for allowing me to use their equipment, without which I could not have
completed my project. I am very grateful to Dr. Michael Leffak for his cloning advice,
which enabled me to complete a cloning step that had plagued me for almost a year.

x

I would like to thank the Microbiology and Immunology Program for providing
me with financial support in the form of a teaching assistantship. This assistantship
allowed me to afford graduate school, but it also gave me the opportunity to teach
students and to recruit one of those students, Renee, to the Brown lab. I would also like
to thank Dr. T. Bubulya and Meredith Rodgers for making my teaching experience
enjoyable.
Finally, I would like to thank my family, especially my daughter Gabby, for their
love and support, and Gabby would like to thank Dr. Brown for giving her Skittles every
time she came to visit the lab.

xi

I. INTRODUCTION

AMP-activated protein kinase
Regulating energy levels is an essential process that occurs in all living
organisms. AMPK (5’-adenosine monophosphate-activated protein kinase), also known
as protein kinase, AMP-activated (PRKAA), is an enzyme that is conserved from yeast to
humans and has important roles in sensing the energy status of the cell to maintain
homeostasis [1-5]. AMPK has been linked to numerous disease states, including
metabolic disorders and cancer, although its role is still not clear and appears to be
context-dependent [6]. Functional AMPK is a heterotrimer that acts to regulate
metabolism and is composed of three subunits, the catalytic alpha subunit and the
regulatory beta and gamma subunits [3,7]. There are two isoforms of the AMPK alpha
subunit, AMPKα1 and AMPKα2, and each isoform has been shown to have overlapping
as well as distinct functions depending on the cell type [3,8-11].

AMPK acts as a metabolic master switch regulating several intracellular systems
including glucose uptake and β-oxidation of fatty acids. AMPK inhibits fatty acid
synthesis by phosphorylating acetyl-CoA carboxylase (ACC) at Ser79 [12]. The energysensing capability of AMPK can be attributed to its ability to detect and react to
1

fluctuations in the AMP: ATP ratio. Stressors, such as muscle contraction or ischemia,
that deplete ATP in the cell result in an elevated AMP: ATP ratio, triggering AMPK
activation. AMPK is phosphorylated at Thr172 of the alpha subunit by LKB1, a known
tumor suppressor [13], and calmodulin-dependent protein kinase kinase β (CaMKKβ)
[14], and this phosphorylation is required for activation. AMP activates AMPK by
inhibiting the dephosphorylation of Thr172 by protein phosphatase-2C [5,8]. AMPK is
also allosterically activated by AMP binding to the γ subunit [8]. Activated AMPK
promotes ATP production and inhibits anabolic pathways that utilize ATP.

Carotid body
In addition to its other roles, AMPK may be involved in oxygen sensing. The
carotid body is a small paired sensory organ which is responsible for sensing oxygen
levels in the carotid artery and signaling through the carotid sinus nerve to regulate the
breathing rate in order to maintain oxygen homeostasis [15]. The carotid body is
composed of two types of cells; type I cells sense oxygen through an unknown
mechanism, and type II cells appear to provide support [16]. AMPK has been reported to
couple hypoxic inhibition of mitochondrial oxidative phosphorylation to excitation of
isolated rat carotid body type I cells [17]. To determine if AMPK is necessary for
oxygen sensing by carotid body type I cells, we decided to generate an AMPK-deficient
rat model to study the ability of the animals to respond to hypoxia. Rats were chosen
because the carotid body has been studied extensively in the rat [16]. It is not known
which isoform of AMPKα may be involved in oxygen sensing or if they can both
perform the same function in the carotid body. For this reason, we wanted to inhibit both
2

isoforms. These rats will be used to determine if AMPK is required in vivo for the
carotid body to upregulate the breathing rate in response to hypoxia.

Studying AMPK activity
Multiple strategies to manipulate AMPK activity have been developed. Drugs
targeting AMPK, such as the activating drug AICAR (5-aminoimidazole-4-carboxyamide
ribonucleoside) and inhibitor Compound C, have been identified, but these
pharmacological agents have been shown to alter other processes in the cell as well [1819]. For example, AICAR is metabolized in the cell into an AMP analogue that is able to
bind AMP-binding sites on other proteins and is also able to inhibit oxidative
phosphorylation independent of its effect on AMPK [18]. Compound C has been shown
to inhibit over 10 kinases, not just AMPK [19]. Therefore, these drugs do not specifically
target AMPK, and alternate methods should be used to alter AMPK activity more
precisely. The generation of AMPKα1 (α1-/-) and α2 (α2-/-) knockout mice have
established critical roles for AMPKα1 and AMPKα2 in the regulation of energy
metabolism and oxygen sensing [3,9,20]. Double knockout of the AMPKα1 and
AMPKα2 isoforms, simultaneously, results in lethality at embryonic day 10.5 [3], so this
model system is not available to study functions that can be performed by both isoforms
of AMPKα. An alternative method to inhibit AMPKα1 and 2 is needed.

RNA interference
Another way to study the activity of AMPK is to block its expression using RNA
interference. RNA interference (RNAi) is a process by which double-stranded RNA
3

(dsRNA) molecules can regulate gene expression. Small interfering RNAs (siRNAs), are
synthetic, 21-nucleotide dsRNA molecules that are complementary to a mRNA transcript
[21]. As shown in Figure 1, when siRNA is introduced into a cell, one strand is
incorporated into the RNA-induced silencing complex (RISC) and binds the
complementary mRNA [22]. This results in destruction of the mRNA transcript by a
member of the Argonaute family of proteins [23], thus preventing translation into protein
[24-25]. The effects of siRNA are transient because the siRNA molecules get diluted as
the cells divide [26]. Therefore, this strategy is not useful for long-term studies.

Short hairpin RNAs (shRNAs) are synthetic RNA molecules that have been
modified to include a stem-loop-stem structure resembling the structure of naturallyoccurring microRNAs (miRNAs). As shown in Figure 1, the hairpin structure of shRNAs
is cleaved by the enzyme Dicer in the cytoplasm into siRNA molecules [27]. shRNAs
are transcribed from DNA templates such as plasmids, and this allows their expression to
be stable and heritable in cell culture [28-31]. The RNA polymerase III promoters U6
and H1, which are the promoters for the U6 small nuclear RNA and histone H1
respectively, are commonly used to drive expression of shRNAs [32]. In addition,
shRNAs can be used to generate transgenic animal models with knockdown of target
proteins as an alternative to classic transgenic animal knockout models. A number of
silencing RNAs against AMPK have been generated [2,10,33-34], but there is no

4

Figure 1. Diagram of RNAi pathway
Diagram of the siRNA and shRNA pathways after transcription of an shRNA from a
DNA template in the nucleus or introduction of synthetic siRNA molecules directly into
the cytoplasm of the cell. Arrows indicate molecules that must be introduced into the cell
through transfection or another method to generate knockdown: DNA template such as a
plasmid or virus (shRNA) or dsRNA molecules (siRNA).
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reported sequence that is able to knock down both catalytic isoforms of AMPKα1 and
AMPKα2 in multiple species. For this reason, we designed an shRNA that is
complementary to a sequence conserved between both catalytic isoforms in human,
mouse, and rat and can be used in any of these three model systems.

Cre-Lox system
We will use Cre recombinase to direct the tissue-specific expression of an shRNA
against AMPKα1 and 2. Cre recombinase is an enzyme that catalyzes site-specific DNA
recombination at sequences called LoxP sites [35]. LoxP sites are 34-basepair stretches
of DNA containing two 13-basepair palindromes separated by an 8-basepair spacer,
which confers directionality to the site; the region of DNA flanked by two LoxP sites is
said to be “floxed” [36]. The Cre enzyme binds to LoxP sites in the DNA and aligns two
sites in the same orientation. It then catalyzes a recombination reaction in which the
floxed DNA sequence and one of the two LoxP sites are excised from the DNA (Figure
2). This technique is used to delete genes or other stretches of DNA. Cre recombinase
has been used to create animal models with tissue-specific knockout of genes by mating
mice with floxed genes to mice with tissue-specific expression of the Cre recombinase
enzyme [originally described in 37]. The offspring resulting from the mating have
knockout of the floxed gene only in tissues where Cre recombinase is expressed. This
powerful technique has been used numerous times to create animal models, especially
when the total body knockout causes embryonic lethality.

7

Figure 2. Diagram of Cre recombinase-mediated recombination
DNA recombination catalyzed by Cre recombinase at LoxP sites located between DNA
regions A and B and regions B and C. Region B is the floxed DNA that is removed
following binding of Cre recombinase at LoxP sites, looping of the DNA, aligning of the
LoxP sites, and recombination.
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C

Tissue-specific knockdown
Tissue-specific knockdown will be accomplished by disrupting the U6 promoter,
which controls the expression of the shRNA, with a floxed sequence of DNA containing
an RNA polymerase III stop sequence. The promoter will not be active, and the shRNA
will not be transcribed, unless the extra DNA is removed. Figure 3 shows a diagram of a
standard shRNA under control of the U6 promoter, an shRNA with a disrupted U6
promoter, and a schematic of the recombination that would occur following the
expression of Cre recombinase. Tissue-specific expression of Cre recombinase will
allow the promoter to be restored, and the shRNA will only be made in tissues that
express Cre recombinase.

The tissue-specific promoter that was chosen to direct the expression of Cre
recombinase is the tyrosine hydroxylase (TH) promoter. Tyrosine hydroxylase is an
enzyme that catalyzes the conversion of L-tyrosine to DOPA, the rate-limiting step of
catecholamine synthesis [38], and it is only expressed in carotid body type I cells [39]
and in the brain and adrenal glands [40]. The shRNA will only be made in cells that
express tyrosine hydroxylase. The TH promoter was chosen because TH is known to be
highly expressed in carotid body type I cells, and TH is frequently used as a marker for
type I cells [39]. It is possible that there could be off-target effects on breathing
regulation due to knockdown of AMPKα in other tissues.

Both of the components necessary to generate tissue-specific knockdown of
AMPKα1 and 2 will be cloned into one construct that can be used to make a lentivirus.
10

Figure 3. Structures of shRNA constructs
(A) Structure of the shRNA under control of the U6 promoter. (B) Structure of the
shRNA with disrupted U6 promoter. (C) Diagram of recombination that would occur
following expression of Cre recombinase with the construct shown in B.
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Figure 4 shows a diagram of this final construct. The virus will contain both the shRNA
with a disrupted U6 promoter and the Cre recombinase gene under control of the TH
promoter. Also shown in Figure 4 is a diagram of the recombination that would occur in
tissues that activate the TH promoter and, therefore, express Cre recombinase. This
construct will be made into a lentivirus because the virus can be used to infect embryos in
order to generate a transgenic rat strain with tissue-specific knockdown of AMPKα1 and
2.

Summary
In this study, we demonstrate the production of a novel shRNA that
simultaneously targets both AMPKα1 and α2 isoforms. This shRNA is 100%
complementary to a nucleotide sequence conserved in the human, mouse, and rat forms
of the AMPKα1 and AMPKα2 mRNA and causes a significant reduction in AMPKα1
and 2 protein levels. Knockdown of AMPKα1 and 2 also reduces phosphorylation of
ACC, a direct target of AMPK. This new shRNA will be useful for analyzing the
numerous functional roles of AMPKα1 and 2, and it will later be used to generate a
transgenic rat strain with tissue-specific silencing of AMPKα1 and 2. These rats will be
studied to determine if AMPK is involved in the oxygen-sensing capabilities of carotid
body type I cells.
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Figure 4. Structure of virus producing tissue-specific silencing
(A) Structure of the virus. (B) Diagram of recombination that would occur in tissues that
activate the TH promoter and express Cre recombinase.

14

Figure 4
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II. MATERIALS AND METHODS

Cloning and cell culture
Restriction enzymes and buffers used in ligation experiments were purchased
from Invitrogen (Carlsbad, CA) and used according to the manufacturer’s specifications.
Digested vector DNA was dephosphorylated using Antarctic Phosphatase (New England
Biolabs, Ipswich, MA, M0289S) prior to ligation. Digested DNA was separated using
agarose gel electrophoresis, and DNA fragments for ligation were isolated using an
E.Z.N.A. Gel Extraction Kit (Omega Bio-Tek, Norcross, GA, D2501-01) according to the
manufacturer’s specifications. All ligations were performed using a rapid ligation kit
(Roche, Basel, Switzerland, 11635379001) according to the manufacturer’s
specifications. Lentiviral plasmids were transformed into One Shot Stbl3 Chemically
Competent Cells (Invitrogen, Carlsbad, CA, C7373-03) according to the manufacturer’s
specifications. Plasmid DNA was isolated from bacterial cultures using E.Z. Nucleic
Acid Plasmid Mini (D6942-02) or Maxi (D6922-02) Kits from Omega Bio-Tek
(Norcross, GA) according to the manufacturer’s specifications. Sequences were verified
by DNA sequencing (AGCT, Inc., Wheeling, IL). Table 1 contains a summary of base
plasmids used as starting materials for cloning. Table 2 contains a summary of all cloned
plasmid constructs.
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A multiple cloning site, or MCS, (ClaI-XbaI-NdeI-HindIII-EcoRV-EcoRI-PstISmaI-SalI-XbaI-BamHI) was purchased as DNA oligonucleotides from IDT, Inc.
(Coralville, IA), annealed, and ligated into pLenti6/V5 D-TOPOTM (Invitrogen, Carlsbad,
CA, K4955-01) containing an enhanced green fluorescent protein (GFP) gene using ClaI
and BamHI to create pLv-MCS-GFP.

The rat tyrosine hydroxylase promoter was isolated from 4.5ThpAL+ (provided
by Dr. Karen O’Malley, Washington University School of Medicine) using EcoRV and
EcoRI and cloned into the MCS to create pLv-MCS-THp-GFP. This construct was used
to generate a stable pool of HEK293 cells expressing GFP under control of the TH
promoter.

The GFP gene was removed from pLv-MCS-GFP using BamHI and ApaI, and the
sticky ends were removed by blunting with a Quick Blunting Kit (New England Biolabs,
Ipswich, MA, E1202L) according to the manufacturer’s specifications. The blunt ends
were ligated together to create pLv-MCS-∆GFP. The TH promoter was cloned into this
construct using EcoRV and EcoRI to create pLv-MCS-THp-∆GFP.

The Cre recombinase gene with a Myc tag was isolated from pCAG-CreMyc
(purchased from Addgene, Inc., Cambridge, MA) using polymerase chain reaction (PCR)
(Platinum Taq DNA Polymerase High Fidelity, Invitrogen, Carlsbad, CA, 11304-011)
according to the manufacturer’s specifications. Primers were purchased from IDT, Inc.
(Coralville, IA). The PCR reaction added EcoRI sites to both ends of CreMyc, and a
17

HindIII site was added to the 3’ end inside the EcoRI site. EcoRI was used to clone the
CreMyc PCR product into pLv-MCS-THp-∆GFP to create pLv-MCS-THp-CreMyc.
This construct was used to generate a stable pool of HEK293 cells expressing CreMyc
under control of the TH promoter.

RNA oligonucleotides for siRNA experiments and DNA oligonucleotides for
shRNA experiments were synthesized by ACGT, Inc. (Wheeling, IL). DNA oligos were
annealed and ligated into pENTRTM/U6 using the BLOCK-iTTM U6 RNAi entry vector
kit (Invitrogen, Carlsbad, CA, K4944-00) according to the manufacturer’s instructions to
create the plasmid shRNAs (pENTR-U6-AMPKα1&2shRNA Loops 2-4) and control
shRNA (pENTR-U6-control shRNA loop 3). pENTR plasmids were transformed in One
Shot TOP10 Chemically Competent E. coli cells (Invitrogen, Carlsbad, CA, C4040-10)
according to the manufacturer’s specifications.

An RNA polymerase III stop site flanked by two LoxP sites (LoxP-Stop-ClaIXhoI-LoxP) was purchased as DNA oligonucleotides with 5’ phosphorylated overhangs
complementary to NdeI sticky ends from IDT, Inc. (Coralville, IA) and annealed. The
annealed oligo contained overhangs that could be directly ligated into the pENTR-U6AMPKα1&2shRNA-Loop3 plasmid digested with NdeI to create pENTR-U6-LoxPAMPKα1&2shRNA-Loop3. Successful ligation of the oligo into the NdeI site of the
vector removed the NdeI site, and the ligated DNA was digested with NdeI prior to
transformation to remove religated vector DNA. To test the recombination, pENTR-U6LoxP-AMPKα1&2shRNA-Loop3 DNA was recombined with Cre recombinase (New
18

Table 1. Base plasmids used to create constructs
Plasmid name:
pLv-CMV-GFP
4.5ThpAL+

pCAG-CreMyc

pEGFP

Use:
Base plasmid for TH
promoter-driven constructs
Source of rat TH promoter
to drive expression of GFP
and CreMyc
Source of CreMyc DNA to
be cloned into TH
promoter-driven construct,
ubiquitously expressed
CreMyc for control in
transfection
Ubiquitously expressed
CMV promoter-driven
GFP for control in
transfections
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Table 2. Cloned constructs
Plasmid name:
pLv-MCS-GFP

Backbone:
pLenti6

Cloning strategy:
CMV in pLv-CMVGFP replaced with
MCS

pLv-MCSTHp-GFP

pLenti6

TH promoter cloned
in front of GFP in
pLv-MCS-GFP

pLv-MCS∆GFP

pLenti6

GFP gene removed
from pLv-MCS-GFP

pLv-MCSTHp-∆GFP

pLenti6

TH promoter cloned
into pLv-MCS-∆GFP

pLv-MCSTHp-CreMyc

pLenti6

pENTR-U6AMPKshRNA
pENTR-U6LoxP-AMPK
shRNA loop 3
pENTR-U6LoxP-AMPK
shRNA loop 3MCS
pENTR-U6LoxP-AMPK
shRNA loop 3THp-CreMyc
pLv-BlockiTDEST- U6LoxP-AMPK
shRNA loop 3THp-CreMyc

CreMyc PCR product
from pCAG-CreMyc
cloned after TH
promoter
pENTR/U6 shRNA oligos ligated
into backbone
pENTR/U6 LoxP oligo ligated
into NdeI site in U6
promoter
pENTR/U6 MCS cloned after
shRNA

pENTR/U6 THp-CreMyc from
pLv-MCS-THpCreMyc cloned after
shRNA
pLenti6/
U6-LoxP-AMPK
BLOCKshRNA-THpiT-DEST
CreMyc cassette
from pENTR
construct cloned into
lentiviral backbone
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Use:
Base plasmid for
TH promoterdriven GFP and
CreMyc constructs
Used to make TH
promoter-driven
GFP virus for
infection and as
TH promoterdriven GFP for
transfection in cells
Base plasmid for
TH promoterdriven CreMyc
Base plasmid for
TH promoterdriven CreMyc
TH promoterdriven CreMyc for
transfection in cells

Status:
Completed

Expression of
shRNA for
transfection in cells
Disrupted shRNA,
tested with
recombinant Cre
Base plasmid for
final construct

Completed

Base plasmid for
final construct

Not completed

Lentiviral plasmid
to make final
lentivirus

Not completed

Completed

Completed

Completed

Completed

Completed

Not completed

England Biolabs, Ipswich, MA, M0298S) according to the manufacturer’s specifications,
digested with XhoI and PvuII, and electrophoresed on a 1% agarose gel.

NIH3T3, HEK293, and PC12 cells were purchased from ATCC, Inc. (Manassas,
VA), and maintained at 37oC supplemented with 5% CO2 in HyClone DMEM/High
glucose (Thermo Scientific, Waltham, MA, SH30022.01) with 10% FBS (Biowest,
Nuaillé, France, S01520) and 1% HyClone antibiotic/antimycotic solution (Thermo
Scientific, Waltham, MA, SV30079.01). Cells were passaged at 90% confluency.

siRNA and shRNA design
cDNA sequences of human, mouse, and rat AMPKα1 and AMPKα2 were aligned
using MacVector software. The sequence ATGATGTCAGATGGTGAATTT was
identified in the NCBI database (http://www.ncbi.nlm.nih.gov/index.html) and
determined to be 100% identical in all cDNAs and corresponded to the following
nucleotide regions: hAMPKα1 (gene accession number Q96E92) 553-573, mAMPKα1
498-518, rAMPKα1 487-507, hAMPKα2 558-578 (gene accession number P54646.2),
mAMPKα2 596-616, rAMPKα2 494-514). The global siRNA and shRNA were
designed to target this region. A second sequence, AATGGAATATGTGTCTGGAGG,
was 100% conserved in the cDNA sequences of human, mouse, and rat AMPKα2. This
region contains two base pair mismatches with the mouse and rat AMPKα1 sequences
and three base pair mismatches with the human AMPKα1 sequence. A control shRNA
was designed to be identical to the AMPKα1 and 2 shRNA with the exception of 5 base
pair mismatches. The sequence of the control shRNA
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(ACGACGTCAGCTGGTGCATGT) did not contain significant homology to known
genes in the human, mouse, or rat genomes as determined by analysis in the
NCBI/BLAST program. shRNA stem loop design was based upon previous studies
[TLB unpublished data, 27].

Transfection and infection
HEK293 cells were seeded on 60 mm plates at 1.2x106 cells/plate and transfected
with a 3:1 ratio of Lipofectamine2000 (Invitrogen, Carlsbad, CA, 11668019) to DNA
according to the manufacturer’s specifications. NIH3T3 cells were simultaneously
seeded on 60 mm plates at 8x105 cells/plate and transfected with a 5:1 ratio of
Metafectene (Biontex, San Diego, CA, T020-1.0) to DNA according to the
manufacturer’s specifications. Transfection efficiency was determined by replicate
transfection with ubiquitously expressed GFP (pEGFP). Cells were lysed 24, 48, or 72
hours post- siRNA transfection and 72 hours post-shRNA (pENTR-U6-AMPKα1&2
shRNA Loops 2-4) transfection for analysis. Stable pools were generated by treating
transfected HEK293 cells (transfected with pLv-MCS-THp-GFP or pLv-MCS-THpCreMyc) with 10 µg/ml Blasticidin (InvivoGen, San Diego, ant-bl-1). PC12 cells were
seeded on 60 mm plates at 5x104 cells/plate and infected by adding 2 ml of lentiviral
THp-GFP (made from pLv-MCS-THp-GFP plasmid) for 24 hrs. Cells were maintained
under standard culture conditions and examined for GFP expression after 72 hours.
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Western blotting
Whole cell lysates were collected with Cell Lysis Buffer (Cell Signaling, Beverly,
MA, 9803) supplemented with Complete Protease Inhibitor Tablets (Roche, Basel,
Switzerland, #11836153001). Lysates were briefly sonicated on ice, and protein
concentrations were determined by the Bradford method [41-42]. Lysates were boiled in
Laemmli reducing buffer, and 50 µg of total protein from each sample was
electrophoresed on 10% SDS polyacrylamide gels for AMPK isolation or 8% SDS
polyacrylamide gels for ACC isolation. Proteins were transferred to an Immobilon
PVDF Membrane (Millipore, Billerica, MA, IPVH08100) and blocked in Tris-buffered
saline containing 0.1% Tween-20 and 5% nonfat, dry milk. Antibodies purchased from
Cell Signaling (Beverly, MA, anti-AMPKα1 #2795; anti-AMPKα #2603; anti-phosphoACC #3661; anti-ACC #3676) were used overnight at a dilution of 1:1000 in Trisbuffered saline with 0.1% Tween-20 and 5% bovine serum albumin. Antibodies
purchased from GeneTex (San Antonio, TX, anti-AMPKα2,GTX111373) were used
overnight at a dilution of 1:2000 in Tris-buffered saline with 0.1% Tween-20 and 5%
nonfat, dry milk. Anti-actin C4 monoclonal antibody (Seven Hills Bioreagents,
Cincinnati, OH) was used at a 1/10,000 dilution for 1 hr at room temperature. Anti-Myc
antibody (clone 9E10) was purchased from Millipore, Inc. (Billerica, MA). Horseradish
peroxidase-conjugated secondary antibodies were purchased from Promega (Madison,
WI, anti-rabbit IgG, HRP conjugate #W401B; and anti-mouse IgG, HRP-conjugate
#W402B) and used at a dilution of 1:25,000 for one hour. Blots were developed using
SuperSignal West Pico Chemiluminescent Substrate kit (Thermo Scientific, Waltham,
MA, 34080), exposed to x-ray film, and visualized by chemiluminescence.
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Data analysis
Western blot data was analyzed with NIH ImageJ software (rsbweb.nih.gov/ij/) to
quantitate protein levels. For shRNA experiments, three to six independent experiments
were performed for each blot, and the results were averaged. Statistical significance was
determined using one-way ANOVA.
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III. RESULTS

siRNA-mediated knockdown of AMPK alpha
AMPKα was first knocked down using siRNA in order to identify viable
sequences that can be targeted with an shRNA to generate stable knockdown. To
generate a global AMPKα1 and 2 gene knockdown, we aligned the cDNA sequences of
human, mouse, and rat AMPKα1 and 2 and identified a single 21 bp sequence conserved
in each (Table 3). We generated an siRNA targeting this sequence to determine if it
could knock down AMPKα1 and AMPKα2 simultaneously. We also made an siRNA
against a region of AMPKα2 that is conserved in human, mouse, and rat (Table 4). The
siRNAs were transfected in mouse fibroblast cells, NIH3T3s, at two different
concentrations, and the cells were lysed 24, 48, and 72 hours post-transfection and run on
a western blot (Figure 5). The lower concentration, 20 nm, was used to ensure there were
few off-target effects. The higher concentration, 100 nm, was used to ensure the greatest
knockdown of the target protein. The global siRNA knocked down AMPKα1 and 2
protein levels at both concentrations at all three time points compared to mocktransfected control. The AMPKα2 siRNA caused a moderate knockdown of AMPKα1
and 2. Surprisingly, it caused a greater knockdown of AMPKα1 than AMPKα2 though
the siRNA was not a perfect match for AMPKα1. The transient nature of siRNA25

Table 3. Identification of a globally conserved sequence in AMPK alpha 1 and 2
AMPKα1

AMPKα2

Human

AAC ATG ATG TCA GAT GGT GAA TTT TTA

Mouse

AAC ATG ATG TCA GAT GGT GAA TTT TTA

Rat

AAC ATG ATG TCA GAT GGT GAA TTT TTA

Human

AAT ATG ATG TCA GAT GGT GAA TTT CTG

Mouse

AAT ATG ATG TCA GAT GGT GAA TTT CTA

Rat

AAT ATG ATG TCA GAT GGT GAA TTT CTA

AMPKα1&2 global siRNA

ATG ATG TCA GAT GGT GAA TTT

cDNA sequences for human, mouse, and rat AMPKα1 and α2 were aligned using the
MacVector software program. Mismatches are shown in bold.
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Table 4. Identification of a conserved sequence in AMPK alpha 2
AMPKα1

AMPKα2

Human

GGT GAT GGA ATA TGT CTC AGG AGG AGA

Mouse

GGT GAT GGA ATA TGT CTC TGG AGG AGA

Rat

GGT GAT GGA ATA TGT CTC TGG AGG AGA

Human

GGT AAT GGA ATA TGT GTC TGG AGG TGA

Mouse

GGT AAT GGA ATA TGT GTC TGG AGG TGA

Rat

GGT AAT GGA ATA TGT GTC TGG AGG TGA

AMPKα2 specific siRNA

AAT GGA ATA TGT GTC TGG AGG

cDNA sequences for human, mouse, and rat AMPKα1 and α2 were aligned using the
MacVector software program. Mismatches are shown in bold.
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Figure 5. siRNA-mediated knockdown of AMPK alpha 1 and 2 in NIH3T3 cells
(A) Western blots of NIH3T3 cells transfected with AMPKα2 or AMPKα1&2 siRNA at
20 nM or 100 nM. Cells were lysed after 24 hrs, 48 hrs, or 72 hrs and separated with
SDS-PAGE. Blots were probed with anti-AMPKα1, anti-AMPKα2, and anti-actin.
Representative actin blot shown in A. (B-C) Relative AMPKα1 (B) and AMPKα2 (C)
protein levels in siRNA-transfected NIH3T3 cells compared to mock-transfected control
cells 24, 48, and 72 hours post-transfection after normalizing to actin loading control.
Data was analyzed with NIH ImageJ software.
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mediated knockdown is evident in Figure 5 as a less efficient knockdown 72 hrs after
transfection. These results prompted us to select the sequence of the global AMPKα1
and 2 siRNA to generate an shRNA that can be used to stably knock down AMPKα1 and
2.

shRNA-mediated knockdown of AMPK alpha
To generate stable knockdown of AMPKα1 and 2, we used the AMPKα1 and 2
siRNA sequence to generate an shRNA. Though the loop structure of the shRNA is
cleaved prior to binding of the RNA to the target mRNA, the sequence of the loop has a
significant impact on the activity of the shRNA [43]. We will refer to the most
commonly used shRNA loop sequence (TTCAAGAGA) as the Brummelkamp loop [29].
However, this particular loop begins with two thymidine residues. RNA polymerase III,
which drives shRNA production from the U6 promoter in the pENTRTM vector,
recognizes a stretch of four or more thymidine residues as a stop site [44]. Therefore, this
loop cannot be used if the stem sequence of the shRNA ends in two or more thymidine
residues, as is the case for the AMPKα1 and 2 shRNA. For this reason, we needed to
identify different loop sequences that did not begin with thymidine (Table 5). We tested
three loops, referred to as loops 2-4, in NIH3T3 cells (Figure 6). A fourth loop, loop 1
was not tested because the plasmid was found to contain a mutation after sequencing.
Two of the loops, loops 3 and 4, significantly knocked down protein levels of both
isoforms of AMPKα. Loops 3 and 4 were the complement and the reverse, respectively,
of the Brummelkamp loop. We found that the complement of the Brummelkamp loop,
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Table 5. Design of shRNA loop sequences and sequences of shRNA oligos
Brummelkamp loop

TTCAAGAGA

Loop 2

CCACACC

Loop 3

AAGTTCTCT

Loop 4

AGAGAACTT

Loop 2 top oligo

CACCGATGATGTCAGATGGTGAATTTCC
ACACCAAATTCACCATCTGACATCAT

Loop 2 bottom oligo

AAAAATGATGTCAGATGGTGAATTTGGT
GTGGAAATTCACCATCTGACATCATC

Loop 3 top oligo

CACCGATGATGTCAGATGGTGAATTTAA
GTTCTCTAAATTCACCATCTGACATCAT

Loop 3 bottom oligo

AAAAATGATGTCAGATGGTGAATTTAGA
GAACTTAAATTCACCATCTGGACATCATC

Loop 4 top oligo

CACCGATGATGTCAGATGGTGAATTTAG
AGAACTTAAATTCACCATCTGACATCAT

Loop 4 bottom oligo

AAAAATGATGTCAGATGGTGAATTTAAGT
TCTCTAAATTCACCATCTGACATCATC

Loop sequences and sequences of DNA oligos ordered from ACGT, Inc., and ligated into
pENTRTM to create plasmid shRNAs.
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Table 6. Design of global AMPK alpha 1 and 2 shRNA and corresponding control
shRNA
AMPKα1&2 Loop 3 shRNA sequence
ATG ATG TCA GAT GGT GAA TTT

TAC TAC AGT CTA CCA TCC AAA
Control shRNA sequence
ACG ACG TCA GCT GGT GCA TGT

TGC TGC AGT CGA CCA CGT ACA

Base pair mismatches in the control shRNA are shown in bold.
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Figure 6. shRNA-mediated knockdown of AMPK alpha 1 and 2 in NIH3T3 cells
with different loop sequences
(A) Representative western blot of NIH3T3 cells transfected with AMPKα1 and 2
shRNA with loops 2-4 and control shRNA. Cells were lysed after 72 hrs. Lysates were
electrophoresed with SDS-PAGE and immunoblotted with anti-AMPKα1, antiAMPKα2, and anti-actin. (B) Relative AMPKα1 and 2 protein levels in shRNAtransfected NIH3T3 cells compared to control shRNA-transfected NIH3T3 cells after
normalizing to actin loading control. Relative protein levels are listed as percentages of
control. Results are representative of 3 independent experiments. Data was analyzed
with NIH ImageJ software. Error bars represent the standard error of the mean. (*)
P<0.05. (**) P<0.01. (***) P<0.001.
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loop 3, resulted in the greatest knockdown, 54% knockdown of AMPKα1 and 55%
knockdown of AMPKα2, and this shRNA was chosen for further study. We created a
control shRNA containing five base-pair mismatches from the target 21 nt siRNA
sequence using the loop 3 sequence (Table 6). AMPKα1 and 2 protein levels in cells
transfected with the control shRNA were equivalent to mock-transfected controls (data
not shown). This control shRNA was used for all shRNA experiments.

Knockdown of AMPK alpha in mouse and human cells
We transfected the shRNA into mouse NIH3T3 cells and human embryonic
kidney HEK293 cells to demonstrate its ability to knock down AMPKα1 and 2 in
multiple species (Figure 7). The shRNA significantly knocked down protein levels of
both isoforms of AMPKα in both species. In mouse NIH3T3 cells, AMPKα1 and
AMPKα2 protein levels were knocked down 49% and 44%, respectively, compared to
the control shRNA. In human HEK293 cells, AMPKα1 and AMPKα2 protein levels
were knocked down 63% and 72%, respectively, compared to the control shRNA. The
shRNA was likely more effective in human cells than in mouse cells due to the increased
transfection efficiency in HEK293 cells, as determined by replicate transfections with
GFP. Representative fluorescence micrographs of NIH3T3 and HEK293 cells
transfected with GFP are shown in Figure 8 to demonstrate the difference in transfection
efficiency between the cell types. Both transfections were performed as controls during
shRNA experiments simultaneously and under the same conditions as the shRNA
transfections. Transfection with GFP was more efficient in HEK293 cells than in
NIH3T3 cells.
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Figure 7. shRNA-mediated knockdown of AMPK alpha 1 and 2 in mouse and
human cells
(A) Representative western blot of NIH3T3 and HEK293 cells transfected with AMPKα1
and 2 loop 3 shRNA and control shRNA. Cells were lysed after 72 hrs. Lysates were
electrophoresed with SDS-PAGE and immunoblotted with anti-AMPKα1, antiAMPKα2, and anti-actin. (B-C) Relative AMPKα1 and 2 protein levels in shRNAtransfected NIH3T3 cells (B) and HEK293 cells (C) compared to control shRNAtransfected cells after normalizing to actin loading control. Relative protein levels are
listed as percentages of control. Results are representative of 3-6 independent
experiments. Data was analyzed with NIH ImageJ software. Error bars represent the
standard error of the mean. (***) P<0.001.
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Figure 8. Transfection efficiency of NIH3T3 and HEK293 cells
(A-B) Representative fluorescence micrographs of NIH3T3 cells (A) and HEK293 cells
(B) transfected with ubiquitously expressed CMV promoter-driven GFP (pEGFP) as
replicate controls for shRNA transfection experiments. Fluorescence was checked after
72 hrs.
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Functional knockdown of AMPK alpha
To show functional knockdown of AMPK by the loop 3 shRNA, we looked for
reduced phosphorylation of a direct target, acetyl-CoA carboxylase (ACC). Transfection
of HEK293 cells with the loop 3 AMPKα1 and 2 shRNA did not alter total ACC protein
levels; however, it did cause a significant reduction in the phosphorylated form of ACC
(phospho-ACC, Figure 9). The protein level of phosphorylated ACC was knocked down
41% by the AMPKα1 and 2 shRNA compared to the control shRNA. The total ACC
protein levels in the AMPKα1 and 2 shRNA-treated cells compared to the control
shRNA-treated cells were nearly identical and unaffected by transfection.

Expression of TH promoter-driven constructs
To test the expression of the tyrosine hydroxylase promoter-driven GFP plasmid
(pLv-MCS-THp-GFP), we transfected HEK293 cells and selected with blasticidin to
generate a stable pool of transfected cells. The cells expressed GFP (Figure 10 A),
indicating the construct is functional. HEK293 cells express TH [45], even though they
were isolated from kidney cells, because they have been found to more closely resemble
neuronal cells than kidney cells [46]. The TH promoter-driven GFP was also expressed
in PC12 cells (Figure 10 B), which are rat pheochromocytoma cells that express TH [47].
HEK293 cells were transfected with the TH-driven CreMyc plasmid (pLv-MCS-THpCreMyc) and selected with blasticidin to generate a stable pool of cells. The extracts
from these cells were run on a western blot along with positive control lysates of
HEK293 cells transiently transfected with the ubiquitously expressed CreMyc plasmid
(pCAG-CreMyc) (Figure 10 C). Both transfected cell populations expressed CreMy
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Figure 9. shRNA-mediated knockdown of AMPK alpha activity in HEK293 cells
(A) Representative western blot of HEK293 cells transfected with AMPKα1 and 2 loop 3
shRNA and control shRNA. Cells were lysed after 72 hrs. Lysates were electrophoresed
on an 8% SDS-PAGE gel and immunoblotted with anti-phospho-ACC, anti-ACC, and
anti-actin. Lysates from one experiment were also electrophoresed on a 10% SDS-PAGE
gel and immunoblotted with anti-AMPKα and anti-actin. (B) Phospho-ACC protein
levels in shRNA-transfected HEK293 cells compared to control shRNA-transfected cells
as a percentage of total ACC levels after normalizing to actin loading control. Relative
protein levels are listed as percentages of control. Results are representative of 3
independent experiments. Data was analyzed with NIH ImageJ software. Error bars
represent the standard error of the mean. (**) P<0.01.
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Figure 10. Expression of TH promoter-driven constructs
(A) Fluorescence micrograph of HEK293 cells transfected with TH promoter-driven GFP
plasmid (pLv-MCS-THp-GFP). Transiently transfected cells were selected with 10
µg/ml Blasticidin to generate a stable pool of transfected cells. (B) Fluorescence
micrograph of PC12 cells infected with TH promoter-driven GFP lentivirus. (C) Western
blot of HEK293 cells transfected with TH promoter-driven CreMyc plasmid (pLv-MCSTHp-CreMyc) and ubiquitously expressed CreMyc plasmid (pCAG-CreMyc). Cells were
lysed after 72 hrs. Lysates were electrophoresed on a 10% SDS-PAGE gel and
immunoblotted with anti-Myc.
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(38 kDa), and all HEK293 cell populations did not express endogenous Myc (49 kDa) as
expected [48].

Cre recombinase-driven recombination
The U6 promoter was disrupted with two LoxP sites flanking an RNA polymerase
III stop site. The DNA was tested with recombinant Cre to ensure the floxed sequence
was removed. The recombined DNA was digested with XhoI and PvuII and
electrophoresed on an agarose gel to determine the size of the resulting fragments (Figure
11). The recombination removed 52 bp, including the XhoI site, from the DNA. This
can be seen in the gel as a decrease in the amount of 770 and 279 bp fragments and the
appearance of a 997 bp fragment (indicated with an arrow). The reaction is reversible, so
the reaction proceeds to equilibrium. The banding pattern indicates the recombination
occurred as expected.
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Figure 11. In vitro recombination of disrupted U6 promoter construct with Cre
recombinase
Agarose gel of pENTR-U6-LoxP-AMPKα1&2shRNA Loop 3 construct recombined with
Cre recombinase. Lane 1 contains a ladder. Lanes 2 and 3 contain pENTR-U6-LoxPAMPKα1&2shRNA DNA digested with XhoI and PvuII. Lane 3 was recombined with
Cre recombinase prior to digestion.
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IV. DISCUSSION

AMPK alpha 1 and 2 knockdown
AMPK is a key regulator of cellular metabolism, and it exerts its function through
the catalytic alpha subunit. Knocking down both isoforms of the catalytic subunit is a
way to study the function of AMPK; however, previous knockdowns of AMPKα were
only designed to be effective in one model system. We originally tested an shRNA
against AMPKα1 and 2 that had been previously published [34], but the target sequence
was not conserved between multiple species. Therefore, we were unable to test the
knockdown in a convenient system. This led us to develop an siRNA that can target both
catalytic α1 and α2 isoforms of AMPK in human, mouse, and rat cells. This new siRNA
could be used in any number of systems because the sequence is conserved. Because
siRNA only causes a transient knockdown in protein levels, we converted the siRNA into
an shRNA. The shRNA caused a significant reduction in AMPKα protein levels in both
human and mouse cells. We hypothesize the shRNA will also be effective in rat cells
because the sequence is 100% conserved.

When designing an shRNA, the loop that is used can have a significant impact on
the knockdown of the target protein [43]. We chose to test three different loops to
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determine which is the most effective. The complement of the most commonly reported
loop (loop 3) was found to be the most effective. This loop can be used for shRNAs that
end in thymidine residues as an alternative to the most common loop to prevent the
formation of an RNA polymerase III stop site.

The shRNA was cloned into the pENTRTM/U6 Entry vector from Invitrogen.
From this plasmid, the shRNA can be transferred into other expression systems such as
the lentiviral Block-iTTM Dest vector from Invitrogen, which can be used to make a
lentivirus containing the shRNA. Lentiviral infection with the shRNA should cause
greater knockdown due to a higher efficiency of transduction.

Knockdown of protein levels does not necessarily correspond to a reduction in
activity of the target protein. For this reason, we wanted to ensure AMPKα activity was
also reduced by the shRNA. ACC is phosphorylated at Ser79 by AMPKα [49]. ACC
catalyzes the production of malonyl-CoA from acetyl-CoA, thus providing the starting
material for fatty acid synthesis. When ATP is depleted from the cell, ACC is inactivated
by AMPK, and acetyl-CoA is used for energy production in the citric acid cycle. The
reduction in phospho-ACC levels indicates that AMPK activity, not just protein levels,
was reduced by the shRNA.

Tissue-specific constructs
The tyrosine hydroxylase promoter will be used to generate tissue-specific
expression of the shRNA. A plasmid containing TH promoter-driven GFP was generated
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to visualize where the TH promoter was expressed. GFP was expressed in HEK293 and
PC12 cells, which are TH positive, so the promoter is functional. Also, the PC12 cells
were infected with a lentivirus containing TH promoter-driven GFP. This lentivirus was
over 12 kb in size. The generally accepted size limit for a lentivirus to be efficiently
packaged into viral particles is about 10 kb. The expression of GFP in these cells
indicates that a larger virus is still capable of being effectively packaged and infecting
cells. This is important because the final virus will be about 12 kb, so we would expect
the final virus to be functional from this result.

A plasmid containing TH promoter-driven Cre recombinase with a Myc tag (pLvMCS-THp-CreMyc) was generated to direct tissue-specific expression of Cre
recombinase. Cre, when used with the shRNA with a disrupted promoter, will restore the
promoter and allow the shRNA to be made in TH positive cells only. The Myc tag was
detected in lysates of a stable pool of HEK293 cells transfected with pLv-MCS-THpCreMyc, indicating the plasmid is functional.

Disrupted U6 promoter
The U6 promoter of the shRNA was disrupted by a floxed sequence of DNA
containing an RNA polymerase III stop site. The cloning to create this construct was
challenging because the floxed sequence of DNA was ordered as small, approximately 90
bp, DNA oligos that were annealed and digested before ligation into the NdeI site of the
vector. The small size of the insert and the lack of directional cloning made the reaction
very unfavorable. To overcome this issue, we designed oligos that would have overhangs
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following annealing that are complementary to the NdeI site in the vector. The oligos
were synthesized with phosphorylated 5’ ends, which are required by DNA ligase, to
allow them to be ligated directly into the digested vector following annealing. Ligation
of this oligo into the vector would remove the NdeI site in the vector, so we were able to
digest the ligated DNA with NdeI before transformation to get rid of any vector DNA
that religated with itself. This strategy selected for successful ligations and removed the
large amount of background vector religation. The floxed sequence of DNA was
removed from the promoter in vitro following treatment with Cre recombinase. This
indicates the floxed sequence is able to be removed as expected, and the promoter should
be restored following expression of Cre recombinase.

Future work
In the future, the HEK293 cells stably expressing TH promoter-driven CreMyc
will be transfected with the shRNA with a disrupted promoter to test the recombination
mediated by Cre to determine if the U6 promoter function is restored following excision
of the floxed sequence. The TH-driven plasmids must also be tested to ensure they are
truly tissue specific and are not expressed in TH negative cells. In order to make the final
virus, the cassette containing the TH promoter-driven Cre recombinase will be transferred
to the same vector as the shRNA with the disrupted promoter.

The construct with the disrupted promoter must still be tested to determine if the
shRNA is no longer expressed. If the floxed sequence of DNA is not sufficient to disrupt
the U6 promoter, and there is still some expression of the shRNA, a GFP reporter gene
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can be cloned into the sequence. This reporter gene is very large and will effectively
prevent transcription from the promoter. The construct with the disrupted promoter must
also be tested to determine if the shRNA is expressed after recombination with Cre
recombinase. Following recombination with Cre, one 34 basepair LoxP site remains in
the DNA. The distance between crucial elements of the U6 promoter is critical to its
proper function, but the sequence of DNA between the elements is not [50]. If the extra
DNA from the LoxP site prevents efficient binding of RNA polymerase III to the restored
U6 promoter, an alternate strategy is to remove part of the U6 promoter so the LoxP site
remaining after recombination replaces it. This should ensure the promoter will be
functional following recombination.

In future studies, the tissue-specific shRNA will be used to generate a rat
transgenic strain with knockdown of AMPKα1 and 2 only in cells that express TH. A
lentivirus containing both the shRNA with the disrupted U6 promoter and the TH
promoter-driven Cre recombinase will be used to infect fertilized rat embryos. A
technique called embryo transfer will be used to transplant the infected embryos into
pseudopregnant mothers [51-52]. The pups will have the transgene integrated into every
cell, but the shRNA will only be made in cells that express TH. Therefore, the rats will
have tissue-specific knockdown of AMPKα1 and 2. We expect the knockdown should
not result in embryonic lethality because it is not a complete knockout, so some AMPKα
protein is still made, and it is only knocked down in some tissues. Previously, a mouse
strain with total body knockout of AMPKα1 and liver-specific knockout of AMPKα2
was generated [3,18]. The mice were viable, so this indicates that tissue-specific double
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knockout models are possible, although it is currently not known which tissues require
expression of AMPKα1 and 2 for survival of the animals. It is also important to
remember that the rats will have knockdown of AMPKα1 and 2, not knockout. It is
possible that minimal expression of AMPKα1 and 2 could allow the animals to survive.
If the animals are not viable, an alternative is to use a conditional expression system, such
as a Tet-On system [53], to control the temporal expression of Cre recombinase. Using
this system, Cre recombinase would not be expressed in TH-positive tissues until the
animals are treated with the antibiotic tetracycline or a derivative, doxycycline. In this
way, knockdown of AMPK would not occur until after the animals are already born, so
defects in development would be avoided. The rats will be used in future studies to
determine if breathing regulation by carotid body type I cells is impaired by knockdown
of AMPK. If AMPK is necessary for carotid body type I cells to respond to hypoxia, the
rats will not be able to upregulate their breathing rate in response to hypoxia. These
studies will help elucidate the role of AMPK in oxygen sensing by the carotid body.

In conclusion, we have generated a new shRNA that can significantly knock
down protein levels and activity of AMPKα1 and 2 in multiple species. This shRNA will
later be used to generate a transgenic rat strain with tissue-specific knockdown of
AMPKα1 and 2.
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V. APPENDIX
Abbreviations

AMPK- 5’-Adenosine Monophosphate-Activated Protein Kinase
PRKAA- Protein-Kinase, AMP-activated
ACC- Acetyl-CoA Carboxylase
CaMKKβ- Calmodulin-Dependent Protein Kinase Kinase β
AICAR- 5-Aminoimidazole-4-Carboxyamide Ribonucleoside
RNAi- RNA Interference
dsRNA- Double-Stranded RNA
siRNA- Small Interfering RNA
RISC- RNA-Induced Silencing Complex
shRNA- Short Hairpin RNA
miRNA- Micro RNA
TH- Tyrosine Hydroxylase
MCS- Multiple Cloning Site
GFP- Green Fluorescent Protein
PCR- Polymerase Chain Reaction
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